Status:
UNKNOWN
Perioperative Administration of Gabapentin for Reducing Inhalational Anesthetic Consumption
Lead Sponsor:
Cairo University
Conditions:
Gabapentin
Eligibility:
All Genders
18-60 years
Phase:
EARLY_PHASE1
Brief Summary
Gabapentin, a structural analog of gamma aminobutyric acid (GABA), was introduced within the us as an anticonvulsant, used clinically to treat epilepsy. The drug causes amino acids release within the ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients aged from 18 to 60 years.
- ASA I-II.
- Undergoing craniotomy for intracranial tumors.
- Exclusion criteria:
- Patient refusal
- Patients younger than 18 or above 60 years old
- patients with (ASA) physical status ≥ III
- patients with compromised cardiovascular, renal, hepatic or neurological function
- Known allergy to study drug.
- Contraindication or chronic use (consistent use for longer than 3 months) to any of the study drugs
- Suffered from severe psychiatric disease or drug addiction;
- History of parenteral or oral analgesic intake within the last 48hours
Exclusion
Key Trial Info
Start Date :
June 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2023
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT05301205
Start Date
June 25 2021
End Date
July 30 2023
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo university
Cairo, Egypt, 11562